Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials

International Journal of Cardiology
Matteo MonamiEdoardo Mannucci

Abstract

The publication of the results of LEADER and SUSTAIN-6 trials suggested a possible beneficial effect of the class of GLP-1 receptor agonists on cardiovascular morbidity and mortality. The aim of the present meta-analysis is to collect and synthetize all available evidence on the effect of GLP-1 receptor agonists on cardiovascular events and mortality. A Medline search for GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, or semaglutide) was performed, collecting all randomized clinical trials with a duration >11weeks, enrolling patients with type 2 diabetes, and comparing a GLP-1 receptor agonist with placebo or any other non-GLP-1 receptor agonist drug. The principal outcome of this analysis was the effect of GLP-1 receptor agonists on all-cause and cardiovascular mortality, overall (fatal plus nonfatal) myocardial infarction, stroke, and heart failure. Out of 113 trials fulfilling inclusion criteria (mean duration 41.7±38.2weeks), 32, 25, 48, 43 and 32 reported at least one event for all-cause and cardiovascular mortality, overall (fatal plus nonfatal) myocardial infarction, stroke, and heart failure, respectively. In GLP-1 receptor agonist-treated patients, all-cause mortality, cardiova...Continue Reading

Citations

Sep 8, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Jul 22, 2018·Diabetes/metabolism Research and Reviews·Annunziata NuscaGermano Di Sciascio
Aug 30, 2018·Journal of Managed Care & Specialty Pharmacy·Michael HeileMichael Shannon
Jan 11, 2019·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·F BarkasH Milionis
Feb 28, 2019·Expert Opinion on Drug Safety·Vasilios G AthyrosMichael Doumas
Mar 1, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Cheli Melzer-CohenAvraham Karasik
Jul 3, 2019·Current Vascular Pharmacology·Dimitrios PatouliasAsterios Karagiannis
Mar 10, 2020·Canadian Journal of Physiology and Pharmacology·Chris R TriggleMorley D Hollenberg
Aug 30, 2019·Cardiovascular Diabetology·Yue FeiBernard Man Yung Cheung
Dec 22, 2019·Reviews in Endocrine & Metabolic Disorders·Giovanni CoronaFrancesco Lombardo
Jan 4, 2021·Atencion primaria·Domingo Orozco-BeltránJorge Navarro Pérez
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Qi-You DingXiao-Lin Tong
Feb 6, 2020·Current Vascular Pharmacology·Dimitrios PatouliasAsterios Karagiannis
Aug 9, 2021·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Edoardo MannucciUNKNOWN SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes
Aug 28, 2020·Diabetes Spectrum : a Publication of the American Diabetes Association·Alan J Sinclair, Ahmed H Abdelhafiz
Aug 3, 2019·Clinical Diabetes : a Publication of the American Diabetes Association·Kenneth S HershonOla Odugbesan

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

© 2022 Meta ULC. All rights reserved